Guggulphospholipid Liposome Targeting Precision
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as abnormal cell growth, cardiovascular issues, and memory loss lack effective targeted delivery mechanisms, and existing therapies for cholesterol regulation and inflammation are not adequately addressed by existing pharmacological approaches.
Innovation Solution
Development of novel guggulphospholipid compositions conjugated with E-guggulsterone and Z-guggulsterone or their derivatives, which are synthesized and used in targeted delivery systems like liposomes to treat various human and animal diseases, including cancer, cardiovascular diseases, and cognitive dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional pharmacological treatments are used for cholesterol regulation and inflammation, then general therapeutic effects are achieved, but targeted delivery to specific tissues and cells is insufficient
Solution Approach 1:
The patent employs liposome-based delivery systems where guggulphospholipid conjugates are nested within liposomal structures. These liposomes can be further encapsulated within larger delivery vehicles or formulated as complex lipid assemblies, creating nested delivery architectures that enable precise targeting while managing complexity through hierarchical organization.
Solution Approach 2:
The guggulphospholipid conjugates serve as intermediary molecules that bridge the gap between the guggulsterone core structure and the target biological systems. These conjugates act as carriers and mediators that facilitate targeted delivery to specific tissues and cells, improving precision without requiring overly complex delivery mechanisms.
2Adaptability or versatility
If multiple disease treatments are addressed separately, then specific therapeutic effects are achieved, but comprehensive disease management is limited
Solution Approach 1:
The guggulphospholipid conjugates exhibit multi-functionality, simultaneously addressing multiple disease states including cardiovascular issues, inflammation, cognitive dysfunction, and abnormal cell growth. The same core structure with varying phospholipid conjugates can target different physiological pathways, enabling a single platform to provide versatile therapeutic coverage across multiple disease categories.
Solution Approach 2:
The therapeutic approach is segmented into different guggulphospholipid conjugate variants, each tailored for specific disease indications. By dividing the overall therapy into specialized conjugate types (e.g., for cardiovascular, neuro, or anti-cancer applications), the system achieves versatility while maintaining manageable complexity through modular design.
3Reliability
If existing cholesterol and inflammation therapies are used, then general therapeutic benefits are obtained, but effective targeted delivery to specific cell types is not achieved
Solution Approach 1:
The patent applies local quality by creating guggulphospholipid conjugates with specific phospholipid moieties that are selectively recognized by particular cell types and tissues. Different conjugates are designed with distinct molecular features that confer preferential affinity for specific cellular targets, enabling precise cellular targeting while maintaining reliable therapeutic effects at the site of action.
Data Source
AI summary
The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.